Market revenue in 2023 | USD 825.0 million |
Market revenue in 2030 | USD 1,707.6 million |
Growth rate | 11% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.07% in 2023. Horizon Databook has segmented the U.S. head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest head and neck cancer therapeutics market in North America. Increased incidence of head and neck cancer, recent U.S. FDA approvals for anticancer drugs, and increased awareness about cancer diagnosis and treatments are some of the factors driving the market.
The high prevalence of head and neck cancer in the country is driving the demand for advanced therapeutics. For instance, according to the American Society of Clinical Oncology (ASCO), in 2023, the number of new head and neck cancer cases in the U.S. was estimated to be 66,920, with an estimated 15,400 related deaths.
Oropharynx cancer is a type of head and neck cancer that occurs in the middle throat behind the mouth. The number of new oropharynx cancer cases was estimated to increase from 12,775 in 2020 to 13,785 by 2030, according to the International Agency for Research on Cancer (IARC).
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account